Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)-mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis for this impaired immunogenicity, despite the overall high mutational load of KRAS-mutant lung cancers, remains obscure. Here, we report that LKB1 loss results in marked silencing of stimulator of interferon genes (STING) expression and insensitivity to cytoplasmic double-strand DNA (dsDNA) sensing. This effect is mediated at least in part by hyperactivation of DNMT1 and EZH2 activity related to elevated S-adenylmethionine levels and reinforced by DNMT1 upregulation. Ectopic expression of STING in KL cells engages IRF3 and STAT1 signaling downstream of TBK1 and impairs cellular fitness, due to the pathologic accumulation of cytoplasmic mitochondrial dsDNA associated with mitochondrial dysfunction. Thus, silencing of STING avoids these negative consequences of LKB1 inactivation, while facilitating immune escape. SIGNIFICANCE: Oncogenic KRAS-mutant lung cancers remain treatment-refractory and are resistant to ICB in the setting of LKB1 loss. These results begin to uncover the key underlying mechanism and identify strategies to restore STING expression, with important therapeutic implications because mitochondrial dysfunction is an obligate component of this tumor subtype.See related commentary by Corte and Byers, p. 16.This article is highlighted in the In This Issue feature, p. 1.

[1]  P. Tamayo,et al.  Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. , 2018, Cancer cell.

[2]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[3]  P. Tamayo,et al.  Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses , 2018, Nature Medicine.

[4]  E. Hara,et al.  Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells , 2018, Nature Communications.

[5]  K. Rogers,et al.  BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis , 2018, Science.

[6]  T. Han,et al.  Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. , 2018, Molecular cell.

[7]  Samuel F. Bakhoum,et al.  Chromosomal instability drives metastasis through a cytosolic DNA response , 2017, Nature.

[8]  Zhi Wei,et al.  Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.

[9]  G. Wei,et al.  ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. , 2018, Cancer research.

[10]  STINGing Antitumor Immunity into Action. , 2018, Cancer discovery.

[11]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[12]  D. Hayes,et al.  LKB1 loss links serine metabolism to DNA methylation and tumorigenesis , 2016, Nature.

[13]  D. Barbie,et al.  Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. , 2016, Seminars in cell & developmental biology.

[14]  G. Barber,et al.  Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis. , 2016, Cancer research.

[15]  J. Massagué,et al.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer , 2016, Nature.

[16]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[17]  G. Barber.  STING: infection, inflammation and cancer , 2015, Nature Reviews Immunology.

[18]  Elizabeth E Gray,et al.  DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway , 2015, Science.

[19]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[20]  N. Grishin,et al.  Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation , 2015, Science.

[21]  Travis J Cohoon,et al.  Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. , 2014, Cancer discovery.

[22]  G. Barber,et al.  Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling , 2013, Cell.

[23]  Koji Kadota,et al.  TCC: an R package for comparing tag count data with robust normalization strategies , 2013, BMC Bioinformatics.

[24]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[25]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.